key: cord-0697087-5yqhtx6m
authors: Lapić, Ivana; Radić Antolic, Margareta; Horvat, Ivana; Premužić, Vedran; Palić, Jozefina; Rogić, Dunja; Zadro, Renata
title: Association of polymorphisms in genes encoding prothrombotic and cardiovascular risk factors with disease severity in COVID‐19 patients: A pilot study
date: 2022-04-21
journal: J Med Virol
DOI: 10.1002/jmv.27774
sha: faed2c6ace215d7a51682e36aa4da436ce3c8a91
doc_id: 697087
cord_uid: 5yqhtx6m

The present study aimed to assess the association of 16 polymorphisms in genes encoding prothrombotic and cardiovascular risk factors with COVID‐19 disease severity: FV G1691A, FV H1299R, FII G20210A, MTHFR C677T, MTHFR A1298, factor XIII V34L, PAI‐1 4G/5G, EPCR haplotypes (A1/A2/A3), eNOS −786 T > C, eNOS G894T, LTA C804A, ACE I/D, ITGB3 PIA1/A2, ITGA2B Baka/b, β‐Fbg −455 G > A and ApoB R3500Q. The study included 30 patients with severe COVID‐19 and 49 non‐severe COVID‐19 patients. All studied polymorphisms except ITGA2B Baka/b were determined using multilocus genotyping assays CVD StripAssays (ViennaLab Diagnostics), while ITGA2B was genotyped using a real‐time PCR method based on TaqMan technology. A higher frequency of carriers of at least one ITGB3 PIA2 allele was found in severe COVID‐19 patients (p = 0.009). The distribution of genotypes was significantly different for ß‐Fbg −455 G > A (p = 0.042), with only three homozygous AA genotypes found among severe COVID‐19 patients. The association with an increased risk for severe COVID‐19 was found for ITGB3, with carriers of at least one ITGB3 PIA2 allele having a 3.5‐fold greater risk of severe COVID‐19 (p = 0.011). Genotype distribution differences were obtained for the combinations of FV H1299R and FXIII V34L (p = 0.026), ITGB3 PIA1/A2 and ITGA2B Baka/b (p = 0.024), and ACE I/D and PAI‐1 4G/5G (p = 0.046). ITGB3 polymorphism emerged as an independent risk factor for severe COVID‐19 and homozygosity for ß‐Fbg −455 G > A mutation could contribute to disease severity. The combined effect of polymorphisms in genes encoding prothrombotic and cardiovascular risk factors could further contribute to disease severity.

| 1 dysfunction or failure. [1] [2] [3] Such exacerbation of COVID-19 is associated with immune system dysregulation accompanied by excessive release of inflammatory cytokines which in turn creates a hyperinflammatory and procoagulant milieu. However, the susceptibility to develop such serious complications is individual and probably a result of a complex interplay that includes several underlying factors such as comorbidities, endothelial dysfunction, oxidative stress but also genetic risk factors. 4, 5 Prothrombotic and cardiovascular complications are the most prevalent adverse events in patients suffering from COVID-19, related to poor prognosis and higher mortality rates. 6, 7 Numerous studies have suggested underlying genetic predisposition as a contributing factor to developing these serious complications. So far, the most studied genes in this context are the ones encoding angiotensin-converting enzymes 1 and 2 (ACE1 and ACE2 genes), since ACE2 is the cellular receptor specifically involved in the binding of SARS-CoV-2 to the nasopharyngeal mucosa and other tissues. The main function of ACE1 is to regulate ACE2 expression through angiotensin II levels, hence regulating blood pressure, systemic vascular resistance, and vasoconstriction. [8] [9] [10] Increased expression of ACE2 receptor caused by ACE1 D allele and a single-nucleotide polymorphism in the ACE2 gene (rs2285666) results in an imbalance of the ACE1/ACE2 arms, consequent disruption of the renin-angiotensinaldosterone system and has been associated with disease severity and poor outcome in COVID-19. 9,10 Furthermore, a limited number of studies have investigated the impact of individual prothrombotic risk factors on COVID-19 severity. Among these, the plasminogen activator inhibitor-1 (PAI-1) 4G/5G gene polymorphism was investigated in a single study so far and was found to be associated with post-COVID-19 osteonecrosis mediated by thrombosis. 11 Furthermore, Ponti et al. 12 suggest the involvement of methylenetetrahydrofolate reductase (MTHFR) C677T polymorphism in the incidence and severity of COVID-19. However, the complexity of the clinical course and underlying complications evidenced in severe COVID-19 patients implies that an array of other genetic risk factors might be involved in the pathobiology of COVID-19. Therefore, studies that investigate the genetic background of proteins involved in thrombosis and cardiovascular-associated complications in COVID-19 patients are strongly advocated. 13 The aim of the present study was to perform a comprehensive analysis covering a selection of polymorphisms in genes encoding prothrombotic and atherosclerotic risk factors in COVID-19 patients and assess their possible association with disease severity.

This cross-sectional study was conducted at the University Hospital Center Zagreb and included 30 patients with a severe form of COVID-19 hospitalized from January to May 2021 at the COVID-19-dedicated intensive care unit (ICU), as well as a control group consisting of 49 patients with non-severe COVID-19. The diagnosis of COVID-19 was confirmed by reverse transcription real-time polymerase chain reaction (PCR) from nasopharyngeal and oropharyngeal swabs. All patients admitted to the ICU presented with bilateral pneumonia and fulfilled at least one of the following criteria for severe COVID-19 14 : oxygen saturation <94%, a ratio of arterial partial pressure of oxygen to fraction of inspired oxygen <300 mmHg, respiratory frequency >30 breaths/min, or lung infiltrates >50%, thus requiring respiratory support.

The following 16 polymorphisms in 12 candidate genes encoding proteins associated with prothrombotic and cardiovascular risk were 

Genomic deoxyribonucleic acid (DNA) was isolated from ethylenediamine-tetraacetic acid whole blood samples drawn into 3-ml tubes (Greiner Bio-One), using the salting-out method, while its quality and quantity were determined spectrophotometrically at 260 and 280 nm using NanoDrop Lite (Thermo Fischer Scientific). DNA extracts were amplified in two parallel multiplex PCRs using biotinylated primers. The size of the amplification products was analyzed by agarose gel electrophoresis.

All studied polymorphisms except ITGA2B Baka/b were determined using commercial multilocus genotyping assays named CVD StripAssays (ViennaLab Diagnostics). The principle of the assays is based on the hybridization of DNA products to a test strip containing allele-specific oligonucleotide probes. Bound biotinylated sequences are detected with streptavidin-alkaline phosphatase and color substrates. The results were read independently by two laboratory professionals. Assay kits were used strictly adhering to the manufacturer's defined protocol. 15, 16 ITGA2B was genotyped using a real-time PCR method based on TaqMan technology on a 7500 Real-time PCR system (Applied Biosystems).

Data distribution normality was assessed using the Shapiro-Wilk test. Categorical data were reported as absolute numbers and proportions, while numerical data as means and standard deviations. 

The study included 30 severe COVID-19 patients (mean age: 61 years, from 33 to 86; 60% males) treated at the ICU and 49 non-severe COVID-19 patients (mean age: 57, from 26 to 88; 51% males). Complications that were developed in severe COVID-19 patients, as well as their comorbidities, are listed in Table 1 .

Distributions of genotype frequencies between severe and nonsevere COVID-19 patients for all assessed polymorphisms are presented in Table 2 . A statistically significant higher frequency of carriers of at least one ITGB3 PIA2 allele was found within the group of severe COVID-19 patients (p = 0.009). The distribution of genotypes among the two compared groups was found to be significantly different for ß-fibrinogen −455 G > A (p = 0.042), with a higher frequency of GA genotypes in non-severe COVID-19 patients, while the only three homozygous AA genotypes were found among severe COVID-19 patients.

The association with an increased risk for severe COVID-19 was not found for the majority of polymorphisms ( Table 3 ). The only exception was ITGB3 for which it emerged that carriers of at least one PIA2 allele have a 3.5-fold greater risk of severe COVID-19 (p = 0.011).

When frequencies of combined polymorphisms were compared, a statistically significant difference in genotype distribution among the two groups of patients was obtained for the combinations of FV H1299R and FXIII V34L, ITGB3 PIA1/A2 and ITGA2B Baka/b, as well as ACE I/D and PAI-1 4G/5G, as shown in Table 4 .

The present study represents the first comprehensive analysis As this polymorphism is associated with elevated plasma levels of the acute phase protein fibrinogen and is considered to be an independent predictor of coronary heart disease, 22 this finding might further support its role in enhancing susceptibility to hyperinflammatory state development, which is one of the hallmarks of severe COVID-19. The role of other assessed polymorphisms was not found to be significant in the progression towards the severe form of COVID-19

in our study population. Contrary to previously published studies, 11 Given the lack of empirical studies in the field, the assumption about the possible involvement of PAI-1 4G/5G in the pathophysiology of COVID-19 was based solely on its well-known role in coagulopathy and inflammation where upregulation of PAI-1 leads to thrombi formation but also induces the secretion of pro-inflammatory cytokines and chemokines by binding to macrophages. 26 

The authors declare no conflicts of interest.

All data from this study are available from the corresponding author upon reasonable request.

The study was approved by the University Hospital Center Zagreb Ethics Committee (Protocol number: 8.1-21/41-2, 02/21-JG).

https://orcid.org/0000-0002-0854-4526

Respiratory follow-up of patients with COVID-19 pneumonia

Coronavirus disease 2019 (COVID-19): the portrait of a perfect storm

Severe covid-19 pneumonia: pathogenesis and clinical management

COVID-19: current understanding of its pathophysiology, clinical presentation and treatment

Endothelial dysfunction, inflammation, and oxidative stress in COVID-19 mechanisms and therapeutic targets

Thrombosis and coagulopathy in COVID-19: current understanding and implications for antithrombotic treatment in patients treated with percutaneous coronary intervention

Cardiovascular complications of COVID-19

COVID19 infections are also affected by human ACE1 D/I polymorphism

Angiotensinconverting enzymes (ACE, ACE2) gene variants and COVID-19 outcome

Angiotensin-converting enzyme (ACE) 1 gene polymorphism and phenotypic expression of COVID-19 symptoms

Relationship between post-SARS osteonecrosis and PAI-1 4G/5G gene polymorphisms

COVID-19 spreading across world correlates with C677T allele of the methylenetetrahydrofolate reductase (MTHFR) gene prevalence

Unpuzzling COVID-19 prothrombotic state: are preexisting thrombophilic risk profiles responsible for heterogenous thrombotic events?

Characteristics of and important lessons from the Coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention

The human platelet antigen-1b (Pro33) variant of αIIbβ3 allosterically shifts the dynamic conformational equilibrium of this integrin toward the active state

Modeling and molecular dynamics of HPA−1a and -1b polymorphisms: effects on the structure of the β3 subunit of the αIIbβ3 integrin

Human platelet alloantigens HPA-1, HPA-2, and HPA-3 polymorphisms associated with extent of severe coronary artery disease

Polymorphisms of platelet membrane glycoprotein Ib associated with arterial thrombotic disease

Role of platelet gene polymorphisms in ischemic pediatric stroke subtypes: a case-control study

The ß fibrinogen gene G-455A polymorphism in Asian subjects with coronary heart disease: a meta analysis

Impact of I/D polymorphism of angiotensin-converting enzyme 1 (ACE1) gene on the severity of COVID-19 patients

Human ACE2 receptor polymorphisms and altered susceptibility to SARS-CoV-2

Investigating the ACE2 polymorphisms in COVID-19 susceptibility: an in silico analysis

An aberrant STAT pathway is central to COVID-19

Association of polymorphisms in genes encoding prothrombotic and cardiovascular risk factors with disease severity in COVID-19 patients: a pilot study